[1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE

Abstract: [1,2,4]triazolo[4,3-a]quinoxalinone compounds of general formula (I) wherein R<1> is POX'X" or alkyl substituted with COX' or POX'X", and X' and X" independently are hydroxy or alkoxy, and R<6>, R<7>, R<8> and R<9> independently are hydrogen; alkyl; halogen; NH2, NO2, CN, CF3, SO2NY'-Y", COZ' wherein Z' is NY'Y" or alkyl and Y' and Y" independently are hydrogen or alkyl; triazolyl; imidazolyl, piperidino, piperazinyl, morpholino or thiomorpholino all rings optionally being subtituted, are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.

Description: [1 ,2,4]triazolo[4,3-a]quinoxalinone derivatives, their Preparation and Use The present invention relates to therapeutically active heterocyclic com¬ pounds, a method of preparing the same, pharmaceutical compositions comprising the compounds, and a method of treating therewith. More specifically, the invention relates to [1 ,2,4]triazolo[4,3-a]quinoxali- none derivatives, which are useful in the treatment of any indication caused by hyperactivity of excitatory amino acids. Various related compounds are known from the prior art. Thus, EP-A-0040401 genetically describes ioie_r aNa triazoloquinoxalin-4- ones substituted at the triazolo ring with e.g. an alkyl, acyl or carbalkoxy group. These compounds are claimed to possess useful anti-hypertensive activity. In US patent No. 5, 153,196 some excitatory amino acid receptor anta¬ gonists and methods for the use thereof are disclosed. The compounds conform inter alia to triazoloquinoxalinones having one substituent being H, alkyl, aromatic or CF 3 at the triazolo ring. Further, international patent publication No. WO 93/20077 deals inter alia with fused quinoxalinone derivatives optionally substituted in the triazolo-ring with lower alkyl which may be substituted by mono- or didower alky amino. L-glutamic acid, L-aspartic acid and a number of other closely related amino acids have in common the ability to activate neurons in the central nervous system (CNS) . Biochemical, electrophysiological and pharmaco¬ logical studies have substantiated this and demonstrated that acidic amino acids are transmitters for the vast majority of excitatory neurons in the mammalian CNS. Interaction with glutamic acid mediated neurotransmission is considered a useful approach in the treatment of neurological and psychiatric diseases. Thus, known antagonists of excitatory amino acids have shown potent anxiolytic (Stephens et al., Psychopharmacology 90, 143- 147, 1 935), anticoπvuisant (Croucher et ai., Science 21 6. 899-901 , 1982) and muscle relaxant properties (Turski et al., Neurosci. Lett. 53^ 321 -326, 1985) . It has been suggested that accumulation of extracellular excitatory amino acids, followed by overstimulation of neurons, may explain the neuronal degenerations seen in neurological disorders such as amyotrophic lateral sclerosis, Parkinsonism, Alzheimer's disease, Huntington's disease, epilepsy, and deficiencies of mental and motor performance seen after conditions of brain ischemia, anoxia and hypoglycemia or head and spinal cord trauma (McGeer et al., Nature 263. 517-519, 1 976; Simon et al.. Science 226, 850-852, 1984; Wieloch, Science 230. 681 -683, 1985; Faden et al., Science 244, 798-800, 1989; Turski et al., Nature 349. 414-41 8, 1991 ). Other possible indications are psychosis, muscle rigidity, emesis and analgesia. Excitatory amino acids exert their actions via specific receptors located postsynaptically or presynaptically. Such receptors are at present con¬ veniently subdivided into three groups bases on electrophysiological and neurochemical evidence: 1 the NMDA (N-methyl-D-aspartate) receptors, 2 the AMPA receptors, and 3 the kainate receptors. L-glutamic acid and L-aspartic acid probably activate all the above types of excitatory amino acid receptors and possibly other types as well. The above mentioned classification of excitatory amino acid receptors into NMDA, AMPA, and kainate receptors is based primarily on the following electrophysiological and neurochemical findings. 1 ) N-methyl-D-aspartate (NMDA) receptors exhibit high selectivity for the excitant NMDA. Ibotenic acid, L-homocysteic acid, D-glutamic acid and trans-2,3-piperidine dicarboxylic acid (trans-2,3-PDA) exert a strong to moderate agonist activity on these receptors. The most potent and selective antagonists are the D-isomers of the 2-amino-5-phosphonocar- boxylic acids, e.g. 2-amino-5-phosphono-valeric acid (D-APV) and 3- [( ± )-2-carboxy-piperazin-4-yl]-propyl-1 -phosphonic acid (CPP), while moderate antagonist activity is shown by the D-isomers of long chain 2- amino dicarboxylic acids (e.g. D-2-amino-adipic acid) and long chain diaminodicarboxylic acids (e.g. diaminopimelic acid). The NMDA-induced synaptical responses have been extensively investigated in the mam¬ malian CNS, especially in the spinal cord (J. Davies et al., J. Physiol. 297. 621 -635, 1979) and the responses have been shown to be strong- ly inhibited by Mg 2 + . 2) AMPA receptors are activated selectively by AMPA (2-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid), other potent agonists being quisqualic acid and L-glutamic acid. Glutamic acid diethyl ester (GDEE) is a selective but very weak antagonist of this site. AMPA receptors are relatively insensitive to Mg 2 + . Glutamate release has long been thought to play a major role in neuronal death resulting from cerebral ischemia (Benveniste, H. et al., J. Neuro- chem. 43_, 1369-1374, 1984). It is well known that NMDA receptor evoked Ca 2 + influx is an important mechanism in ischemic neuronal cell loss. The non-NMDA receptor coupled ionophor is not permeable to calcium. However, the excitation by the Scaffer collaterals in the CA1 region is excerted by non-NMDA receptors, and this fact is of importance for the events in the postischemic period. Recent studies have shown that selective AMPA antagonists have neuroprotectant effects in global ischemia in the gerbil even when given several hours after reperfusion (Sheardown et al., Science 247, 571 -574, 1990). AMPA antagonists are therefore useful in the treatment of cerebral ischemia. 3) Kainate receptors. Excitatory responses to kainic acid are relatively insensitive to antagonism by NMDA-antagonists and by GDEE, and it has been proposed that kainic acid activates a third subclass of acidic amino acid receptor. Certain lactonized derivatives of kainic acid are selective antagonists (O. Goldberg et al., Neurosci. Lett. 23, 187-191 , 1981 ) and the dipeptide 3-glutamyl-glycine also shows some selectivity for kainate receptors. Ca + but not Mg 2+ is a strong inhibitor of kainic acid binding. The affinity of a substance for one or more of the different types of ex- citatory amino acid receptors may be studied in simple binding experi¬ ments. In essence, the method involves incubation of a particular selected radiolabelled ligand and the particular specific substance to be investigated with brain homogenate which contains the receptor. Measu¬ rement of receptor occupancy is made by determination of the radioac- tivity bound to the homogenate and subtraction of nonspecific binding. AMPA receptor binding may be studied by using 3 H-AMPA as radioli- gand. The influence of glutamic acid analogues on secondary effects of glutamate receptor interactions may be studied in vitro by using the phenomenon of spreading depression in chicken retina. Such experi- ments will provide information as to the efficacies (agonist/antagonist) of the test substances. This is in contrast to binding studies, which only provide information on the affinities of the compounds for the receptor. It has now been found that the compounds of the invention have affinity for the AMPA receptors and are antagonists in connection with this type of receptor which makes them useful in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids, especially neuronal degeneration as are observed in amyotrophic lateral sclerosis, Huntington's chorea, Parkinson's disease, epilepsy and senile dementia or mental and motor dysfunctions seen after conditions of brain ischemia, oxygen deficiency, hypoglycemia and head and spinal cord trauma. Other possible indications ar psychosis, muscle rigidity, emesis, acute and chronic inflammatory disease and analgesia. The compounds of the invention are represented by the general formula I wherein R 1 is POX'X" or straight or branched C^-alky! substituted with COX' or POX'X" and X' and X" independently are hydroxy or C^-alkoxy, and R β , R 7 , R 8 and R 9 independently are hydrogen; C^-alky!; halogen; NH 2 ; NO 2 ; CN; CF 3 ; SO 2 NY'Y"; COZ' wherein Z' is NY'Y" or C^-alky!, and Y' and Y" independently are hydrogen or triazolyl; imidazolyl; piperidino; piperazinyl; morpholino; thiomorpholino, which rings are optionally substituted with one or more of phenyl or and phenyl optionally being substituted with and pharmaceuti- cally acceptable salts thereof. The term "C^ β -alkyl" as used herein refers to a straight or branched, saturated hydrocarbon chain having 1 -6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert. butyl, 3-pentyl, neopentyl or n-hexyl. The term "C,. β -alkoxy" as used herein, alone or in combination, refers to a monovalent substituent comprising a group linked through an ether oxygen having its free valence bond from the ether oxygen, e.g. methoxy, ethoxy, propoxy, isopropoxy, cyclopropylmethoxy, butoxy, pentoxy. The term "halogen" as used herein means fluorine, chlorine, bromine and iodine. In a preferred embodiment of the invention R 1 is C.. β -alkyl substituted with COX' or POX'X". In another preferred embodiment of the invention R 6 , R 7 , R 8 and R 9 are independently hydrogen; chlorine; NO 2 ; CN; CF 3 ; piperidino; morpholino; thiomorpholino; piperazinyl; piperazinyl substituted with methyl, phenyl or methoxyphenyl; triazolyl disubstituted with methyl; imidazolyl disubs- tituted with methyl, ethyl, phenyl. In yet another preferred embodiment of the invention R β and R 9 are hydrogen. Preferred compounds of the invention are: 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-(4-methyl-2-phenyl-1 H-imidazol- 1 -yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(4-Methyl-2-phenyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 1-(Ethoxy-hydroxy-phosphorylmethyl)-8-(2-ethyl-4-methyl-1 H-imidazol-1- yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(2-Ethyl-4-methyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-Morpholino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one; 8-Morpholino-1 -(1 -phosphonoethyl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one; 8-Piperidino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo(4,3- a)quinoxalin-4(5H)-one; 1 -(2-Ethoxycarbonylethyl)-8-morpholino-7-trifluoromethyl[1 ,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-morpholino-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one. Other preferred compounds of the invention are: 8-(2,4-Dimethyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluoromethyl- [1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 7-Cyano-8-(2,4-dimethyl-1H-imidazol-1-yl)-1-phosphonomethyl[1,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 8-(2,4-Dimethyl-1H-imidazol-1-yl)-7-nitro-1-phosphonomethyl[1,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 7-Cyano-8-(2-ethyl-4-methyl-1H-imidazol-1-yl)-1-phosphonomethyl[1,2,4- ]triazolo[4,3-a]quinoxalin-4(5H)-one; 7-Cyano-8-morpholino-1-phosphonomethyl[1,2,4]triazolo[4,3-a]quinox- alin-4(5H)-one; 8-Morpholino-7-nitro-1-phosphonomethyl[1 ,2,4]triazolo[4,3-a]quinoxalin- 4(5H)-one; 7-Cyano-1-phosphonomethyl-8-thiomorpholino[1,2,4]triazolo[4,3-a]qu- inoxalin-4(5H)-one; 1-Phosphonomethyl-8-thiomorpholino-7-trifluoromethyl[1,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one; 7-Cyano-1-phosphonomethyl-8-piperidino[1,2,4]triazolo[4,3-a]quinoxalin- 4(5H)-one; 1 -Phosphonomethyl-8-(piperazin-1 -yl)-7-trifluoromethyl[1 ,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one; 7-Cyano-1-phosphonomethyl-8-(piperazin-1-yl)[1,2,4]triazolo[4,3-a]qu- inoxalin-4(5H)-one; 8-(4-Phenylpiperazin-1-yl)-1-phosphonomethyl-7-trifluoromethyl[1,2,4- ]triazolo[4,3-a]quinoxalin-4(5H)-one; 7-Cyano-8-(4-phenylpiperazin-1 -yl)-1 -phosphonomethyl[1 ,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one; 8-(4-(3-Methoxyphenyl)piperazin-1-yl)-1-phosphonomethyl-7-trifluorome- thyl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(4-(4-Methoxyphenyl)piperazin-1-yl)-1-phosphonomethyl-7-trifluorome- thγl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(2,4-Dimethyl-1H-imidazol-1-yl)-1-phosphonoethyl-7-trifluoromethyl- [1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 7-Chloro-8-(2,4-dimethyl-1H-imidazol-1-yl)-1-phosphonomethyl[1,2,4]tri- azolo[4,3-a]quinoxalin-4(5H)-one; 8-(3,5-Dimethyl-1,2,4-triazol-1-yl)-1-phosphonomethyl-7-trifluoromethyl- [1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(4-Methylpiperazin-1-yl)-1-phosphonomethyl-7-trifluoromethyl[1,2,4]- triazolo[4,3-a]quinoxalin-4(5H)-one; 1-(2-Carboxyethyl)-8-(2,4-dimethyl-1H-imidazol-1-yl)-7-trifluoromethyl[1,- 2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 1-(2-Carboxyethyl)-8-(2-ethyl-4-methyl-1H-imidazol-1-yl)-7-trifluorome- thyl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 1-(2-Carboxyethyl)-7-cyano-8-(2,4-dimethyl-1H-imidazol-1-yl)[1,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-(4-phenylpiperazin-1 -yl)-7-trifluoromethyl[1 ,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-(2,4-dimethyl-1 H-imidazol-1 -yl)-7-nitro[1 ,2,4]triaz- olo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-7-cyano-8-morpholino[1 ,2,4]triazolo[4,3-a]quinoxalin- 4(5H)-one; 1 -(2-Carboxyethyl)-8-morpholino-7-nitro[1 ,2,4]triazolo[4,3-a]quinoxalin- 4(5H)-one; 1 -(2-Carboxyethyl)-8-(4-methylpiperazin-1 -yl)-7-trifiuoromethyl[1 ,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-7-chloro-8-(2,4-dimethyl-1 H-imidazol-1 -yl)[1 ,2,4]tria- zolo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-(4-(4-methoxyphenyl)piperazin-1 -yl)-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-piperidino-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one. The compounds of the invention may be present in different tautomeric forms. Therefore the invention includes all such tautomeric forms. Another embodiment of the invention is pharmaceutically acceptable salts of [1 , 2, 4]triazolo[4,3-a]quinoxalinone derivatives of formula I . Such salts include those derived from inorganic and organic acids such as hydrochloric acid, hydrobromic acid, acetic acid, sulfuric acid, nitric acid, oxalic acid, fumaric acid, tartaric acid, etc. Other salts include alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; and ammonium salts. Further, in another aspect the invention relates to a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament, preferably for use as a medicament for treating an indication related to hyperactivity of exitatory neurotransmitters and particularly the AMPA receptors. The invention also relates to a method of preparing the above mentioned compounds. The present compounds of formula I are prepared by a) alkylating a compound having the formula II wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above with ben- zylhalogenide to form a compound of the formula III wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above, and halogenating the compound to form a compound of the formula IV wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above and Q is Br, Cl, or I; and reacting the compound with hydrazine to form a compound of the formula V wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and acylat- ing the compound with an acylchloride with the general formula VI R 1 -COCI (VI) wherein R 1 has the meaning as defined above for a compound of the general formula I wherein X' and X" are to form a compound of the formula VII wherein R\ R β , R 7 , R 8 and R 9 have the meanings defined above, and hydrogenolysis of the compound to form a compound of the formula VIII wherein R\ R β , R 7 , R 8 and R 9 have the meanings defined above, and fol¬ lowed by thermal cyclization and simultaneous deoxygenation to form a compound of formula I, wherein X' and X" independently are hydroxy or b) reacting a compound having the formula IX wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above, and Q is Br, Cl or I, with a compound of the general formula VI R^COCI (VI) wherein R 1 has the meaning as defined above for a compound of the general formula I wherein X' and X" are to form a compound of the formula XI wherein R\ R β , R 7 , R 8 and R 9 have the meanings defined above, and Q is Br, Cl or I, and then either cyclization followed by hydrolysis or simulta¬ neous cyclization and hydrolysis to form a compound of formula I, wherein X' and X"independently are hydroxy or or c) substituting a compound of the formula XII wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above and Z is either halogen or C^-alkoxy with mono-, di-, or trimethoxy substituted benzylamine to form a compound of formula XIII v • wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and reacting the compound with ethyloxalylchloride to form a compound of formula XIV wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and then either hydrogena- tion to form the intermediate cyclized N-hydroxy compound followed by deoxygenation or cyclization by hydrogenation to form a compound of formula XV wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, halogenating the compound of formula XV, reacting the resulting compound with hydrazine followed by acylating with an acylchloride of the general formula VI as defined above, and then cyclization to form a compound of formula XVI wherein R\ R β , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and hydrolysis to form a compound of formula I, wherein X' and X" independently are hydrogen d) hydrolysing a compound of formula I, wherein X' and X" are C β - alkoxy with aqueous base to form a compound of formula I, wherein X' is hydroxy, and X" is C 6 -alkoxy, or e) reacting a compound of formula I, wherein X' is hydroxy or C 6 - alkoxy, and X" is with halotrimethylsilane to form a com¬ pound of formula I, wherein X' and X" are hydroxy. Pharmaceutically acceptable salts may be prepared according to standard procedures by treating a compound of formula I with the appropriate acids or bases. The starting materials for which the preparation is not described herein are either known compounds (e.g. from International appl. no. PCT- DK94/00170) or compounds which may be prepared in analogy with the preparation of known compounds or in analogy with known methods. The pharmacological properties of the compounds of the present inven¬ tion can be illustrated by determining their capability for displacing radioactively labelled 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) from the AMPA type receptors. The antagonistic properties of the compounds is demonstrated by their capability to antagonize quisqualic acid stimulated spreading depression in chicken retina. The displacement activity of the compounds may be shown by determin- ing the IC S0 value which represents the concentration (μM) which causes a displacement of 50% of the specific binding of 3 H-AMPA. The antagonism is measured by determining the IC 50 value which repre¬ sents the concentration which produces a 50% maximal inhibition of quisqualic acid stimulated spreading depression in chicken retina. 3 H-AMPA binding (Test 1 ) 500 μl of thawed rat cerebral cortical membrane homogenate in Tris-HCI (30 mM), CaCI 2 (2.5 mM) and KSCN (100 mM) pH 7.1 were incubated at 0°C for 30 min. with 25 μl 3 H-AMPA (5 nM final concentration) and the test compound and buffer. Nonspecific binding was determined by incubation with L-glutamic acid (600 μM final concentration). The binding reaction was terminated by adding 5 ml of ice-cold buffer fol¬ lowed by filtration through Whatman GF/C glass fibre filters and 2x5 ml wash with ice-cold buffer. Bound radioactivity was measured by scintilla¬ tion counting. iC 50 was determined by Hill analysis of at least four concentrations of test compound. Spreading depression (Test 2) Chicks (3-10 days old) were decapitated, the eyes enucleated and sec¬ tioned along the equatorial plane. After removal of the anterior chamber and the vitreous body, the posterior chamber of each eye was placed in a small petri dish containing a physiological saline solution (P.S.S.) of the following composition (mM) NaCI (100), KCI (6.0), CaCI 2 ( 1 .0), MgSO 4 (1 .0), NaHCO 3 (30), NaH 2 PO 4 (1.0), glucose (20). The solution was saturated with 100% O 2 and maintained at a tempera¬ ture of 26°C. The eyes were initially incubated in normal P.S.S. for 15-30 min. and then transferred to P.S.S. containing quisqualate ( 1 μg/ml). In this "stimulating solution" S.D.s start spontaneously usually from the edge of the retina, and can be easily observed by eye. The time taken for an S.D. to start in each eye was measured. After a further 15 min. of incubation in normal P.S.S. the eyes were transferred to normal P.S.S. containing the test compound and incubated for 15 min. Thereafter the eyes were transferred to a "stimulating solution" containing the same concentration of the test compound. The time taken for an S.D. to start in each eye was measured again. The eyes were then placed back in normal P.S.S. and after 15 min. the time taken for S.D. to start was measured again, in order to assess the degree of recovery from any drug effects. An increase in the time taken for S.D. to start of 30 seconds more than the control time is considered 100% inhibition of S.D. The drug effects therefore are expressed as the percentage maximum response obtained for a given dose. The test value can be quoted therefore as the concen¬ tration (μM) of test substance which produces a 50% maximal inhibition (ICso). Test results obtained by testing some compounds of the present inven¬ tion are shown in the following table 1. Table 1 TEST 1 TEST 2 Compound of IC 50 IC 50 example μM μM 2 0.39 0.40 The pharmaceutical preparations of compositions comprising the com¬ pounds of the invention may be administered to humans or animals by oral, rectal or parenteral route. An effective amount of the active compound or a pharmaceutically acceptable salt thereof may be determined in accordance with the usual factors, such as the nature and severity of the condition and the weight of the mammal requiring treatment. Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or enteral application which do not deleteriously react with the active compounds. Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lac¬ tose, amylose, magnesium stearate, talc, silicic acid, fatty acid monogly- cerides and diglycerides, pentaerythritol fatty acid esters, hydroxyme- thylcellulose, and polyvinylpyrrolidone. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds. Injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil, are par¬ ticularly suitable for parenteral administration. Ampoules are convenient unit dosage forms. Tablets, dragees, or capsules containing talc and/or a carrier or binder or the like are particularly suitable for oral administration. The carrier preferably is lactose and/or corn starch and/or potato starch. A syrup, elixir, or the like can be used in the cases where a sweetened vehicle can be employed or is desired. Generally, the compounds of this invention are dispensed in unit dosage form comprising 0.5-1000 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage. The dosage of the compounds according to this invention is 1 -500 mg/day, e.g. about 50-100 mg per dose, when administered to patients, e.g. humans, as a drug. A typical tablet which may be prepared by conventional tabletting tech¬ niques contains: Core: Active compound (as free compound or salt thereof) 100 mg Colloidal silicon dioxide (Aerosil * ) 1 .5 mg Cellulose, microcryst. (Avicel * ) 70 mg Modified cellulose gum (Ac-Di-Sol * ) 7.5 mg Magnesium stearate 1 mg Coating: HPMC approx. 9 mg "Mywacett * 9-40T approx. 0.9 mg ' Αcylated monoglyceride used as plasticizer for film-coating The free compounds of the present invention which form alkali metal or alkaline earth metal salts may be employed in such salt form. Such alkali metal or earth alkali metal salts are ordinarily formed by reacting the compound with an equivalent amount or excess of the selected alkali metal or earth alkali metal as the hydroxide, frequently and suitably by admixture in the presence of a neutral solvent, from which the salt may be precipitated or recovered in other conventional manner, e.g. by evaporation. Administration of a compound of the invention is often preferably in the form of a pharmaceutically acceptable water-soluble alkali metal or earth alkali metal salt thereof, and orally, rectally, or parenterally in the form of a pharmaceutical composition wherein it is present together with a pharmaceutically acceptable liquid or solid carrier or diluent. The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may be placed into the form of pharmaceutical compo¬ sitions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical composition and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective AMPA antagonistic amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing 1 -500 mg of active ingredient or, more specified 10-200 mg, per tablet, are accordingly suitable representative unit dosage forms. Due to their high degree of AMPA antagonistic activity and their low toxicity, together presenting a most favourable therapeutic index, the compounds of the invention may be administered to a subject, e.g. a living animal body, in need of such treatment, elimination, alleviation, or amelioration of an indication which is sensitive to a change in the AMPA receptor condition, e.g. sclerosis, Parkinsonism, Alzheimer's disease, Huntington's disease, epilepsy, deficiencies seen after ischemia, anoxia, hypoglycemia, head and spinal cord trauma, psychosis, muscle rigidity, emesis and analgesia, often preferably in the form of an alkali metal or earth alkali metal salt thereof, concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parenteral (including subcutaneous) route, in an effec¬ tive amount. Suitable dosage ranges are 1 -500 mg daily, preferably 10-200 mg daily, and especially 50-100 mg daily, depending as usual upon the exact mode of administration, form in which administered, the indication towards which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experi¬ ence of the physician or veterinarian in charge. Such method of treating may be described as the treatment of an indication caused by or related to hyperactivity of the excitatory neurotransmitters, and particularly the AMPA receptors in a subject in need thereof, which comprises the step of administering to the said subject a neurologically effective amount of an AMPA antagonistic compound of the invention, or a pharmaceutically acceptable salt there¬ of. Furthermore, the present invention relates to the use of a compound of the invention for preparing a medicament for treating an indication caused by or related to hyperactivity of the excitatory neurotransmitters, and particularly the AMPA receptors in a subject in need thereof. The invention will now be described in further detail with reference to the following examples: EXAMPLE 1 1-(Ethoxy-hydroxy-phosphorylmethyl)-8-(4-methyl-2-phenyl-1H-imidazol- 1-yl)-7-trifluoromethyl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one a. 1-Benzγloxy-3-chloro-6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-7- trifluoromethylquinoxalin-2(1 H)-one, hydrochloride A solution of 20% phosgene in toluene (18.2 ml, 35 mmol) was added dropwise to a stirred solution of 1-benzyloxy-6-(4-methyl-2-phenyl-1H- imidazoi-1-yi)-7-trifiuoromethylquinoxaline-2,3(1H,4H)-dione (8.8 g, 17.5 mmol) in 100 ml of dry N,N-dimethylformamide at 0°C. The mixture was stirred at room temperature overnight and the precipitated solid was isolated by filtration and washed with ether to give 8.0 g (84%) of the title compound. H-NMR (DMSO-dg): J 2.42 (s, 3H), 5.35 (s, 2H), 7.30-7.61 (m, 10 H), 7.62 (s, 1H), 7.75 (s, 1H), 8.48 (s, 1H). b. 1-Benzyloxy-3-hydrazino-6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-7- trif luoromethylquinoxalin-2( 1 H)-one A mixture of 1-benzyl-3-chloro-6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-7- trifluoromethylquinoxalin-2(1H)-one hydrochloride (2.0 g, 3.6 mmol) and hydrazine hydrate (0.74 ml, 15 mmol) in 40 ml of dichloromethane was stirred at 0°C for 1 h and evaporated to dryness in vacuo. The residue was triturated with water to give 1.59 g (87%) of the title compound. M.p.127-130°C. ^-NMR (DMSO-d β ): δ 2.21 (s, 1H), 5.34 (s, 2H), 7.01 (s, 1H), 7.18 (s, 1H), 7.27 (s, 5H), 7.37-7.45 (m, 3H), 7.48 (s, 1H), 7.51-7.60 (m, 2H). c. 1 -Benzyloxy-3-[2-[(diethoxyphosphoryl)acetyl]hydrazino]-6-(4-methyl- 2-phenyl-1 H-imidazol-1 -yl)-7-trifluoromethylquinoxalin-2( 1 H)-one A solution of (diethoxyphosphoryl)acetyl chloride (0.67 g, 3.1 mmol) in 20 ml of dry tetrahydrofuran was added dropwise to a stirred solution of 1 -benzyloxy-3-hydrazino-6-(4-methyl-2-phenyl-1 H-imidazol-1 -(-yl)-7- trifluoromethylquinoxalin-2(1 H)-one ( 1 .52 g, 3.0 mmol) and dry triethylamine (0.43 ml, 3.1 mmol) in 50 ml of dry tetrahydrofuran. The mixture was stirred overnight at room temperature and then evapo¬ rated to dryness in vacuo. The residue was triturated with water giving 1 .8 g (88%) of the title compound. M.p. > 90°C decomp. 'H-NMR (DMSO-d 6 ) : δ 1 .10-1 .21 (m, 6H), 2.20 (s, 3H), 2.99 (d, 2H), 4.01 (quint., 4H), 5.40 (s, 2H), 7.04 (s, 1 H), 7.24 (s, 6H), 7.37-7.46 (m, 3H), 7.50-7.62 (m, 3H), 10.26 (s, 1 H), 10.38 (s, 1 H). d. 3-[2-[(Diethoxyphosphoryl)acetyl]hydrazino]-1 -hydroxy-6-(4-methyl-2- phenyl-1 H-imidazol-1 -yl)-7-trifluoromethylquinoxalin-2( 1 H)-one A suspension of 1 -benzyloxy-3-[2-[(diethoxyphosphoryl)acetyl]hydra- zino]-6-(4-methyl-2-phenyl-1 H-imidazol-1 -yl)-7-trifluoromethylquinoxalin- 2(1 H)-one (1 .8 g, 2.6 mmol) and 50 mg of 5% palladium on carbon in 50 ml of ethanol was hydrogenated at room temperature and atmos¬ pheric pressure for 9 h. The catalyst was removed by filtration, the filtrate evaporated to dryness in vacuo and the residue finally triturated with ether to give 1 .51 g (97%) of the title compound. M.p. > 1 77°C decomp. ^-NMR (DMSO-d 6 ): δ 1 .10-1 .22 (m, 6H), 2.23 (s, 3H), 2.98 (d, 2H), 4.00 (quint., 4H), 7.1 2 (s, 1 H), 7.18-7.30 (m, 5H), 7.31 (s, 1 H), 7.92 (s, 1 H), 10.24 (s, 2H), 12.52 (br. s, 1 H). e. 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-(4-methyl-2-phenyl-1 H- imidazol-1 -yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one A solution of 3-[2-[(diethoxyphosphoryl)acetyl]hydrazino]-1-hydroxy-6-(4- methyl-2-phenyl-1 H-imidazol-1 -yl)-7-trifluoromethylquinoxalin-2(1 H)-one (1 .5 g, 2.5 mmol) and triphenylphosphine (1 .3 g, 5 mmol) in 50 ml of glacial acetic acid was stirred overnight at 120°C. The cooled mixture was filtered and the isolated product was washed with ether to give 0.64 g (48%) of the title compound. M.p. 303-3- 08°C. 'H-NMR (DMSO-dg): δ 1 .10 (t, 3H), 2.25 (s, 3H), 3.87 (quint., 2H), 3.97 (d, 2H), 7.12 (s, 1 H), 7.14-7.45 (m, 5H), 7.72 (s, 1 H), 8.62 (s, 1 H), 12.4 (s, 1 H). EXAMPLE 2 8-(4-Methyl-2-phenyl-1 H-imidazol-1-yl)-1 -phosphonomethyl-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one Bromotrimethylsilane (1 ml, 7 mmol) was added dropwise to a stirred solution of 1 -(ethoxy-hydroxy-phosphorylmethyl)-8-(4-methyl-2-phenyl- 1 H-imidazol-1 -yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)- one (500 mg, 0.94 mmol) in 20 ml of dry N,N-dimethylformamide. The solution was stirred at room temperature overnight and evaporated to dryness in vacuo. The residue was triturated with 10 ml of water and the precipitated solid was isolated by filtration. Washing with a small amount of water and ethanol gave 0.45 g (95%) of the pure title com¬ pound. M.p. 321 -325°C. 1 H-NMR (DMSO-dg): δ 2.35 (s, 3H), 3.93 (d, 2H), 1.22-1. HI (m, 6H), 7.74 (s, 1 H), 8.79 (s, 1 H), 1 2.4 (s, 1 H) . EXAMPLE 3 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-(2-ethyl-4-methyl-1 H-imidazol-1 - yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1 -benzyloxy-6-(2-ethyl-4-methyl- 1 H-imidazol-1 -yl)-7-trifluoromethylquinoxaline-2,3(1 H,4H)-dione by a method analogous to the method described in example 1 , except that the final product (theoretically 10.8 mmol) was worked up in the follow¬ ing way. To the cooled solution was added 100 ml of dichloromethane and 100 ml of ether. The precipitated solid was isolated by filtration and extracted with boiling water (2 x 100 ml). The aqueous phase was concentrated to about 100 ml and cooled on an ice-bath. The resulting precipitate was isolated by filtration and dried to give 0.90 g ( 17%) of the title compound. 1 H-NMR (CF 3 COOD) : δ 1 .38 (t, 3H), 1 .45 (t, 3H), 2.51 (s, 3H), 2.72- 3.10 (m, 2H), 4.31 (quint., 2H), 4.58 (dd, 2H (partially exchanged)), 7.22 (s, 1 H), 8.32 (s, 1 H), 9.00 (s, 1 H). EXAMPLE 4 8-(2-Ethyl-4-methyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluorome- thyl[ 1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1 -(ethoxy-hydroxy-phosphorylme- thy!)-8-(2-ethyl-4-methyl-1 H-imidazol-1 -yl)-7-trifluoromethyl[1 ,2,4]triaz- olo[4,3-a]quinoxalin-4(5H)-one (870 mg, 1 .8 mmol) by a method analo¬ gous to the method described in example 2. Yield: 710 mg (86%). M.p. > 300°C. 'H-NMR (DMSO-d β ) :rf 1 .10 (t, 3H), 2.20 (s, 3H), 2.27-2.77 (m, 2H), 3.62-3.95 (m, 2H), 7.07 (s, 1 H), 7.85 (s, 1 H), 8.55 (s, 1 H); MS (FAB) : m/e 457 (MH + ) . (C 17 H 1β N β F 3 O 4 P - y 2 H 2 O) Calc : C 43.88 H 3.68 N 1 8.06 Found: C 44.07 H 3.56 N 1 8.02 EXAMPLE 5 8-Morpholino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one a. 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-morpholino-7-trifluoromethyl- [1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1 -benzyloxy-6-morpholino-7- trifluoromethylquinoxaline-2,3(1 H,4H)-dione by a method analogous to the method described in example 1 , except that the final product was isolated in the following way. The mixture was evaporated to dryness in vacuo and the residue was taken up in a mixture of 200 ml of dichloro- methane and 50 ml of chloroform. The resulting solution was extracted with water (6 x 100 ml) and the aqueous solution was evaporated to dryness under reduced pressure by azeotropic distillation with 1 -propanol to give the crude product, which was used without further purification in the following step. b. 8-Morpholino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one The titie compound was prepared from crude 1 -(ethoxy-hydroxy-phos- phorylmethyl)-8-morpholino-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinox- alin-4(5H)-one by a method analogous to the method described in example 2. M.p. > 300°C decomp. (ethanol). 1 H-NMR (DMSO-dg): δ 2.9-3.03 (m, 4H), 3.66-3.78 (m, 4H), 3.98 (d, 2H), 7.68 (s, 1 H), 8.39 (s, 1 H), 12.18 (s, 1 H). EXAMPLE 6 8-Morpholino-1 -(1 -phosphonoethyl)-7-trifluoromethyl[1 ,2,4]t. r iazolo[4,3- a]quinoxalin-4(5H)-one a. 1 -(1 -(Ethoxy-hydroxy-phosphoryl)ethyl)-8-morpholino-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1 -benzyloxy-6-morpholino-7- trifluoromethylquinoxaline-2,3(1 H,4H)-dione by a method analogous to the method described in example 5, except that 2-(diethoxyphosphoryl)- propionyl chloride was used instead of (diethoxyphosphoryl)acetyl chloride. The crude product was used without further purification in the following step. b. 8-Morpholino-1 -(1-phosphonoethyl)-7-trifluoromethyl[1 ,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one The title compound was prepared from crude 1 -(1 -(ethoxy-hydroxy-phos- phoryl)ethyl)-8-morpholino-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinox- alin-4(5H)-one by a method analogous to the method described in example 2, except that the final product was purified by column chroma- tography. M.p. > 300°C decomp. 'H-NMR (DMSO-dg): δ 1.73 (dd, 3H), 2.87-3.02 (m, 4H), 3.68-3.78 (m, 4H), 4.11-4.38 (m, 1H), 7.68 (s, 1H), 8.38 (s, 1H), 12.18 (s, 1H). EXAMPLE 7 8-Piperidino-1-phosphonomethyl-7-trifluoromethyl[1,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one a. 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-piperidino-7-trifluoromethyl- [1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1-benzyloxy-6-piperidino-7- trifluoromethylquinoxaline-2,3(1H,4H)-dione by a method analogous to the method described in example 3, except that the crude product was used without further purification in the following step. b. 8-Piperidino-1-phosphonomethyl-7-trifluoromethyl[1,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one The title compound was prepared from crude 1-(ethoxy-hydroxy-phos- phorylmethyl)-8-piperidino-7-trifluoromethyl[1,2,4]triazolo[4,3-a]quinox- alin-4(5H)-one by a method analogous to the method described in example 2. ^-NMR (DMSO-d g ): δ 1.48-1.72 (m, 6H), 2.83-2.98 (m, 4H), 3.90 (d, 2H), 7.65 (s, 1H), 8.32 (s,1H), 12.12 (s, 1H). EXAMPLE 8 1-(2-Ethoxycarbonylethyl)-8-morpholino-7-trifluoromethyl[1,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one The title compound was prepared from 1 -benzyloxy-6-morpholino-7- trifluoromethylquinoxaiine-2,3( 1 H,4H)-dione and ethyl succinylchloride by a method analogous to the method described in example 1 , except that the final product was worked up in the following way. The cooled mixture was evaporated to dryness in vacuo and purified by flash-chro- matography successively with dichloromethane and ethyl acetate. Trituration with ether afforded the pure product. M.p. 204-210°C. 1 H-NMR (DMSO-dg): δ 1 .22 (t, 3H), 2.88-3.00 (m, 4H), 3.02 (t, 2H), 3.61 -3.82 (m, 6H), 4.12 (q, 2H), 7.71 (s, 1 H), 7.99 (s, 1 H), 1 2.2 (br. s, 1 H). EXAMPLE 9 1 -(2-Carboxyethyl)-8-morpholino-7-trifluoromethyl[ 1 ,2,4]triazoio[4,3- a]quinoxalin-4(5H)-one A suspension of 1 -(2-ethoxycarbonylethyl)-8-morpholino-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one (365 mg, 0.83 mmol) in 10 ml of 2N potassium hydroxide was stirred at room temperature for 3h. The resulting solution was filtered and the filtrate was acidified with 4M hydrochloric acid to give a precipitate. The product was isolated by filtra¬ tion, washed with water and dried to give the title compound. M.p. 1 70- 1 76°C. ' H-NMR (DMSO-d β ) : δ 2.88-3.02 (m, 6H), 3.67 (t, 2H), 3.68-3.80 (m, 4H), 7.71 (s, 1 H), 7.99 (s, 1 H), 1 2.26 (br. s, 1 H) .

Claims: CLAIMS L [1 ,2,4]Triazolo[4,3-a]quinoxalinone compounds of the general formula I wherein R 1 is POX'X" or straight or branched C^-alky! substituted with COX' or POX'X", and X' and X" independently are hydroxy or and R β , R 7 , R 8 and R 9 independently are hydrogen; halogen; NH 2 ; NO 2 ; CN; CF 3 ; SO 2 NY'Y"; COZ' wherein Z' is NY'Y" or C^-alkyl, and Y' and Y" independently are hydrogen or C,. β -alkyl; triazolyl; imidazolyl; piperidino; piperazinyl; morpholino; thiomorpholino, which rings are optionally substituted with one or more of phenyl or and phenyl optionally being substituted with and pharmaceutically acceptable salts thereof. 2 A compound according to claim 1 wherein R 1 is C β -alkyl substi¬ tuted with COX' or POX'X" . 3i A compound according to claim 1 or 2 wherein R β , R 7 , R 8 and R 9 independently are hydrogen; chlorine; NO 2 ; CN; CF 3 ; piperidino; morpho- lino; thiomorpholino; piperazinyl; piperazinyl substituted with methyl, phenyl or methoxyphenyl; triazolyl disubstituted with methyl; imidazolyl disubstituted with methyl, ethyl, phenyl. 4,. A compound according to the previous claim wherein R 6 and R 9 are hydrogen. I A compound according to any of the claims 1 -4 which is 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-(4-methyl-2-phenyl-1 H-imidazol- 1 -yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(4-Methyl-2-phenyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 1 -(Ethoxy-hydroxy-phosphorylmethyl)-8-(2-ethyl-4-methyl-1 H-imidazol-1 - yl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-(2-Ethyl-4-methyl-1 H-imidazol-1 -yl)-1 -phosphonomethyl-7-trifluorome- thyl[1 ,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one; 8-Morpholino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one; 8-Morpholino-1 -(1 -phosphonoethyl)-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one; 8-Piperidino-1 -phosphonomethyl-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one; 1 -(2-Ethoxycarbonylethyl)-8-morpholino-7-trifluoromethyl[1 ,2,4]triazolo- [4,3-a]quinoxalin-4(5H)-one; 1 -(2-Carboxyethyl)-8-morphoiino-7-trifluoromethyl[1 ,2,4]triazolo[4,3- a]quinoxalin-4(5H)-one. 6 A pharmaceutical composition comprising as active component a compound according to any of the claims 1 -5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent. . . A pharmaceutical composition according to claim 6 in the form of a dosage unit containing about 10-200 mg of the active compound. fL The use of a compound according to any of the claims 1 -5 or a pharmaceutically acceptable salt thereof as a medicament. SK The use of a compound according to any of the claims 1 -5 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating an indication related to hyperactivity of excitatory neurotransmitters. 10. A pharmaceutical composition suitable for use in the treatment of an indication related to hyperactivity of the excitatory neurotransmitters, which comprises as active component a compound according to any of the claims 1 -5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent. 1 1 . A method of treating an indication related to hyperactivity of the excitatory neurotransmitters in a subject in need thereof, which com- prises the step of administering to the said subject a neurologically effective AMPA antagonistic amount of a compound according to any of the claims 1 -5 or a pharmaceutically acceptable salt thereof. 12. A method according to claim 1 1 , wherein the indication is related to cerebral ischemia. 13. A method of preparing the compounds of formula I according to claim 1 , which comprises a) alkylating a compound having the formula II wherein R β , R 7 , R 8 and R 9 have the meanings defined above with benz- ylhalogenide to form a compound of the formula III wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and halogenating the compound to form a compound of the formula IV wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above and Q is Br, Cl or I; and reacting the compound with hydrazine to form a compound of the formula V wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above, and acyl- ating the compound with an acylchloride with the general formula VI R 1 -COCI (VI) wherein R 1 has the meaning as defined above for a compound of the general formula I wherein X' and X" are C Lβ -alkoxy to form a compound of the formula VII wherein R\ R 6 , R 7 , R 8 and R 9 have the meanings defined above, and hydrogenolysis of the compound to form a compound of the formula VIM wherein R\ R 6 , R 7 , R 8 and R 9 have the meanings defined above, and fol- lowed by thermal cyclization and simultaneous deoxygenation to form a compound of formula I, wherein X' and X" independently are hydroxy or b) reacting a compound having the formula IX wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and Q is Br, Cl or I, with a compound of the general formula VI R 1 -COCI (VI) wherein R 1 has the meaning as defined above for a compound of the general formula I wherein X' and X" are to form a compound of the formula XI wherein R\ R 6 , R 7 , R 8 and R 9 have the meanings defined above, and Q is Br, Cl or I, and then either cyclization followed by hydrolysis or simulta¬ neous cyclization and hydrolysis to form a compound of formula I, wherein X' and X"independently are hydroxy or C-.g-alkoxy, or c) substituting a compound of the formula XII wherein R β , R 7 , R 8 and R 9 have the meanings defined above and Z is either halogen or with mono-, di-, or trimethoxy substituted benzylamine to form a compound of formula XIII v ' wherein R β , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and reacting the compound with ethyloxalylchloride to form a compound of formula XIV wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and then either hydrogena- tion to form the intermediate cyclized N-hydroxy compound followed by deoxygenation or cyclization by hydrogenatioπ to form a compound of formula XV wherein R 6 , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, halogenating the compound of formula XV, reacting the resulting compound with hydrazine followed by acylating with an acylchloride of the general formula VI as defined above, and then cyclization to form a compound of formula XVI wherein R\ R 6 , R 7 , R 8 and R 9 have the meanings defined above, and V and V" independently are hydrogen or methoxy, and hydrolysis to form a compound of formula I, wherein X' and X" independently are hydrogen or C-.g-alkoxy, or d) hydrolysing a compound of formula I, wherein X' and X" are C,.g- alkoxy with aqueous base to form a compound of formula I, wherein X' is hydroxy, and X" is or e) reacting a compound of formula I, wherein X' is hydroxy or alkoxy, and X" is with halotrimethylsilane to form a com- pound of formula I, wherein X' and X" are hydroxy. 14. A process for the manufacture of a pharmaceutical composition to be used in the treatment of an indication related to hyperactivity of the excitatory neurotransmitters, which process comprises bringing a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof into a galenical dosage form.

Inventors: NIELSEN FLEMMING ELMELUND, NIELSEN, FLEMMING, ELMELUND
Applicants: NIELSEN FLEMMING ELMELUND, NOVONORDISK AS, NIELSEN, FLEMMING, ELMELUND, NOVO NORDISK A/S
Application year: 1995
Main classification: C07D487
IPC codes: A61K31, A61P1, A61P9, A61P25, A61P29, C07D241, C07D249, C07D487, C07F9